Cargando…
Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism
Overexpression and aggregation of α-synuclein (ASyn) are linked to the onset and pathology of Parkinson’s disease and related synucleinopathies. Elevated levels of the stress-induced chaperone Hsp70 protect against ASyn misfolding and ASyn-driven neurodegeneration in cell and animal models, yet ther...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102405/ https://www.ncbi.nlm.nih.gov/pubmed/33798554 http://dx.doi.org/10.1016/j.jbc.2021.100613 |
_version_ | 1783689096358526976 |
---|---|
author | Tao, Jiahui Berthet, Amandine Citron, Y. Rose Tsiolaki, Paraskevi L. Stanley, Robert Gestwicki, Jason E. Agard, David A. McConlogue, Lisa |
author_facet | Tao, Jiahui Berthet, Amandine Citron, Y. Rose Tsiolaki, Paraskevi L. Stanley, Robert Gestwicki, Jason E. Agard, David A. McConlogue, Lisa |
author_sort | Tao, Jiahui |
collection | PubMed |
description | Overexpression and aggregation of α-synuclein (ASyn) are linked to the onset and pathology of Parkinson’s disease and related synucleinopathies. Elevated levels of the stress-induced chaperone Hsp70 protect against ASyn misfolding and ASyn-driven neurodegeneration in cell and animal models, yet there is minimal mechanistic understanding of this important protective pathway. It is generally assumed that Hsp70 binds to ASyn using its canonical and promiscuous substrate-binding cleft to limit aggregation. Here we report that this activity is due to a novel and unexpected mode of Hsp70 action, involving neither ATP nor the typical substrate-binding cleft. We use novel ASyn oligomerization assays to show that Hsp70 directly blocks ASyn oligomerization, an early event in ASyn misfolding. Using truncations, mutations, and inhibitors, we confirm that Hsp70 interacts with ASyn via an as yet unidentified, noncanonical interaction site in the C-terminal domain. Finally, we report a biological role for a similar mode of action in H4 neuroglioma cells. Together, these findings suggest that new chemical approaches will be required to target the Hsp70-ASyn interaction in synucleinopathies. Such approaches are likely to be more specific than targeting Hsp70’s canonical action. Additionally, these results raise the question of whether other misfolded proteins might also engage Hsp70 via the same noncanonical mechanism. |
format | Online Article Text |
id | pubmed-8102405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-81024052021-05-14 Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism Tao, Jiahui Berthet, Amandine Citron, Y. Rose Tsiolaki, Paraskevi L. Stanley, Robert Gestwicki, Jason E. Agard, David A. McConlogue, Lisa J Biol Chem Research Article Overexpression and aggregation of α-synuclein (ASyn) are linked to the onset and pathology of Parkinson’s disease and related synucleinopathies. Elevated levels of the stress-induced chaperone Hsp70 protect against ASyn misfolding and ASyn-driven neurodegeneration in cell and animal models, yet there is minimal mechanistic understanding of this important protective pathway. It is generally assumed that Hsp70 binds to ASyn using its canonical and promiscuous substrate-binding cleft to limit aggregation. Here we report that this activity is due to a novel and unexpected mode of Hsp70 action, involving neither ATP nor the typical substrate-binding cleft. We use novel ASyn oligomerization assays to show that Hsp70 directly blocks ASyn oligomerization, an early event in ASyn misfolding. Using truncations, mutations, and inhibitors, we confirm that Hsp70 interacts with ASyn via an as yet unidentified, noncanonical interaction site in the C-terminal domain. Finally, we report a biological role for a similar mode of action in H4 neuroglioma cells. Together, these findings suggest that new chemical approaches will be required to target the Hsp70-ASyn interaction in synucleinopathies. Such approaches are likely to be more specific than targeting Hsp70’s canonical action. Additionally, these results raise the question of whether other misfolded proteins might also engage Hsp70 via the same noncanonical mechanism. American Society for Biochemistry and Molecular Biology 2021-03-30 /pmc/articles/PMC8102405/ /pubmed/33798554 http://dx.doi.org/10.1016/j.jbc.2021.100613 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Tao, Jiahui Berthet, Amandine Citron, Y. Rose Tsiolaki, Paraskevi L. Stanley, Robert Gestwicki, Jason E. Agard, David A. McConlogue, Lisa Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism |
title | Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism |
title_full | Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism |
title_fullStr | Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism |
title_full_unstemmed | Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism |
title_short | Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism |
title_sort | hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102405/ https://www.ncbi.nlm.nih.gov/pubmed/33798554 http://dx.doi.org/10.1016/j.jbc.2021.100613 |
work_keys_str_mv | AT taojiahui hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism AT berthetamandine hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism AT citronyrose hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism AT tsiolakiparaskevil hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism AT stanleyrobert hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism AT gestwickijasone hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism AT agarddavida hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism AT mcconloguelisa hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism |